-
DEVELOPING AND EVALUATING AN AI-ASSISTED AGENTIC PIPELINE FOR EXCEL-TO-R MIGRATION OF HEALTH ECONOMIC MODELS
Aug 11, 2026, 17:15 PM -
COMPARATIVE SEVERITY OF COVID-19, INFLUENZA, AND RSV HOSPITALIZATIONS IN FRANCE: A PROPENSITY SCORE ANALYSIS USING NATIONAL HOSPITAL DATA
Aug 11, 2026, 17:15 PM -
IMMUNOGLOBULIN PRICE DYNAMICS ACROSS MAJOR MARKETS: EVIDENCE OF SUPPLY-DEMAND PRESSURE BEYOND INFLATION
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS OF ROBOTIC-ASSISTED VERSUS CONVENTIONAL STERNOTOMY FOR MITRAL VALVE REPAIR: A COST-UTILITY ANALYSIS FROM A US HOSPITAL PROVIDER PERSPECTIVE
Aug 11, 2026, 17:15 PM -
EXPONENTIAL GROWTH AND MARKET CONCENTRATION OF PUBLIC REIMBURSEMENT FOR INNOVATIVE CARDIOMETABOLIC PHARMACOTHERAPY IN HUNGARY, 2020-2025
Aug 11, 2026, 17:15 PM -
EXPLORING ADMINISTRATIVE BURDEN AND BURNOUT AMONG ITALIAN ONCOLOGISTS: A CROSS-SECTIONAL SURVEY
Aug 11, 2026, 17:15 PM -
FIVE-YEAR OVERALL SURVIVAL AFTER DIAGNOSIS OF BREAST AND GYNAECOLOGICAL CANCERS BY EDUCATIONAL ATTAINMENT IN SWEDEN AND FINLAND: A NORDIC REAL-WORLD REGISTRY STUDY
Aug 11, 2026, 17:15 PM -
ESTIMATING REAL-WORLD HEALTHCARE COSTS ATTRIBUTABLE TO ADVERSE EVENTS IN PATIENTS WITH METASTATIC BREAST CANCER OR ACUTE MYELOID LEUKEMIA IN TAIWAN
Aug 11, 2026, 17:15 PM -
LEVERAGING JOINT CLINICAL ASSESSMENT TO HARMONIZE HTA DECISIONS ACROSS EUROPE
Aug 11, 2026, 17:15 PM -
A STRUCTURED AI CODE-REVIEW FRAMEWORK FOR VALIDATING R-BASED COST-EFFECTIVENESS MODELS: A HEAD-TO-HEAD COMPARISON WITH HACKATHON-STYLE HUMAN REVIEW
Aug 11, 2026, 17:15 PM -
A TREATMENT IMPACT ANALYSIS OF OCRELIZUMAB IN RELAPSING MULTIPLE SCLEROSIS FROM A GREEK SOCIETAL PERSPECTIVE
Aug 11, 2026, 17:15 PM -
EVALUATING THE IMPACT AND VALUE OF EARLIER SINGLE INHALER TRIPLE THERAPY (SITT) INITIATION IN COPD MANAGEMENT IN ARGENTINA, COLOMBIA AND VIETNAM: A COST-UTILITY MODELING STUDY
Aug 11, 2026, 17:15 PM -
ECONOMIC EVALUATION OF SOMATROPIN STERILE SOLUTION IN NEONATES AND YOUNG CHILDREN WITH GROWTH HORMONE DEFICIENCY-ASSOCIATED HYPOGLYCEMIA
Aug 11, 2026, 17:15 PM -
WHY EMA AND FDA USE THE WRONG MEASURE OF RARITY IN THEIR ORPHAN DRUG LEGISLATIONS
Aug 11, 2026, 17:15 PM -
FROM BARRIERS TO ENABLERS: IDERHA POLICY RECOMMENDATIONS TO ENABLE HEALTH DATA SHARING FOR SECONDARY USE IN THE EUROPEAN HEALTH DATA SPACE
Aug 11, 2026, 17:15 PM -
COST-UTILITY ANALYSIS OF INCLISIRAN ADDED TO STANDARD OF CARE FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE: A PUBLIC PAYER PERSPECTIVE
Aug 11, 2026, 17:15 PM -
QUANTIFYING REAL-WORLD CORTICOSTEROID BURDEN IN MYASTHENIA GRAVIS TREATED WITH NOVEL BIOLOGIC THERAPIES
Aug 11, 2026, 17:15 PM -
CAN NATIONAL EARLY SCIENTIFIC ADVICE SUPPORT JCA READINESS IN THE ABSENCE OF JOINT SCIENTIFIC CONSULTATION?
Aug 11, 2026, 17:15 PM -
WHAT MUST BE EXPLICIT? LESSONS FROM AI-ASSISTED IMPLEMENTATION OF A HEALTH ECONOMIC MODEL
Aug 11, 2026, 17:15 PM -
EVALUATING AI-ASSISTED VERSUS MANUAL TARGETED LITERATURE REVIEWS: A CASE STUDY ON THE BURDEN OF ILLNESS IN FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
Aug 11, 2026, 17:15 PM
